Acute Coronary Syndrome (ACS)
Conditions
Keywords
platelets, Acute coronary Syndrome (ACS), prasugrel, ticagrelor, aspirin
Brief summary
The aims of the study are to: * explore whether platelet reactivity in patients treated wih novel platelet inhibitors is associated with clinical outcome * investigate whether a therapeutic window exist for novel platelet inhibitors * investigate the incidence of adverse events under treatment with novel platelet inhibitors in the real life clinical scenario * investigate the association between genetic polymorphisms, inflammation, platelet reactivity and clinical outcome * investigate synergistic effects between aspirin and novel platelet inhibitors
Interventions
None listed
Sponsors
Medical University of Vienna
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Signed informed consent * Acute coronary syndrome at admission * Planned treatment with novel platelet inhibitors * Age \>18
Exclusion criteria
\* Participation in interventional trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Net clinical benefit. | 1 year | A composite of MACE and BARC=\>2 bleedings. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MACE and Major bleeding | 1 year | MACE: the composite of stent thrombosis, cardiac death and myocardial infarction. Major Bleeding: BARC =\>2, TIMI major, GUSTO moderate-severe-life threatening. |
Other
| Measure | Time frame |
|---|---|
| single endpoints of acute coronary syndrome, myocardial infarction, cardiac death, all-cause death, urgent vessel revascularization (PCI or CABG), stroke. | 1 year |
Countries
Austria
Contacts
Primary ContactJolanta M Siller-Matula, PD MD PhD
Outcome results
None listed